Internal medicine

Pathology

Placebo

Disease

Double blind

Diabetes mellitus

Endocrinology

Urology

Artificial intelligence

Alternative medicine

Type 2 diabetes

Kidney disease

Computer science

Sonar

Medicine

The Lancet

Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial